Interacting Drugs |
Phenobarbital vs Lapatinib |
Security Level |
|
Mechanism |
Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib. |
Management |
If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated. |
Phenobarbital vs Lapatinib
Post Review about Phenobarbital vs Lapatinib Click here to cancel reply.
Other Interactions of Lapatinib
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.